Biotech stocks offer some of the most explosive opportunities.
That is, if you spot the right ones.
For example, some of the hottest ideas can be found in weight loss drugs, cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing.
|
Company: CRISPR Therapeutics (SYM: CRSP) Look at CRISPR Therapeutics (SYM: CRSP), for example. Not long ago, it received US FDA approval for its gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions. With that news, we watched CRISPR jump from about $40 to $70. |
This “AI parallel” stock is expected to grow 12,300% by 2030.
Just $5,000 could turn into a $620,000 windfall.
Full Details Here
|
Company: Eli Lilly (SYM: LLY) Or, look at Eli Lilly (SYM: LLY). Thanks to strong demand for obesity medication, the stock popped from about $580 to $760, and it’s still moving higher. Of course, there are many more. But you get the point. What makes biotech even hotter is that major drug companies are on a shopping spree. Over the next few years, drug giants could lose billions to patent expirations. According to EY analysts, the top 20 giants could lose about $180 billion in sales by the end of the decade. To stop some of the potential bloodshed, companies are building up their pipelines, bringing in fresh new drugs with multi-billion-dollar potential. For example, most recently, Johnson & Johnson said it would acquire Ambrx Biopharma for $2 billion. Pfizer acquired Seagen for $43 billion. |
Crypto Millionaire Names His Five Favorite Altcoins
Crypto pioneer Charlie Shrem has an uncanny knack for spotting the biggest winners, like on Steem, Cindicator, and as much as the 200,000% he made on Bitcoin. Now, he says, there are five coins you must take a look at right away.
I want the details
